Vifor Pharma comments on media speculation

News provided by Vifor Pharma Group
December 13, 2021 17:31 Korea Standard Time

ST. GALLEN, SWITZERLAND--(Business Wire / Korea Newswire) December 13, 2021 -- Regulatory News:

AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR

Vifor is in discussions with CSL about a possible transaction. No decisions have been made yet and there is no time frame for this. Until then, Vifor does not comment on these discussions.

About Vifor Pharma Group

Vifor Pharma Group is a global pharmaceuticals company. It aims to become the global leader in iron deficiency, nephrology and cardio-renal therapies. The company is a partner of choice for pharmaceuticals and innovative patient-focused solutions. Vifor Pharma Group strives to help patients around the world with severe and chronic diseases lead better, healthier lives. The company develops, manufactures and markets pharmaceutical products for precision patient care. Vifor Pharma Group holds a leading position in all its core business activities and consists of the following companies: Vifor Pharma and Vifor Fresenius Medical Care Renal Pharma (a joint company with Fresenius Medical Care). Vifor Pharma Group is headquartered in Switzerland, and listed on the Swiss Stock Exchange (SIX Swiss Exchange, VIFN, ISIN: CH0364749348).

For more information, please visit viforpharma.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211212005150/en/

Website: http://www.viforpharma.com

Contact

Vifor Pharma Group
Media Relations
Nathalie Ponnier
Global Head Corporate Communications
+41 79 957 96 73


Investor Relations
Julien Vignot
Head of Investor Relations
+41 58 851 66 90

This is a news release distributed by Korea Newswire on behalf of this company.